The emergence of new psychoactive substance (NPS) benzodiazepines: a review

Kieran R. Manchester, Emma C. Lomas, Laura Waters, Fiona C. Dempsey, Peter D. Maskell

Research output: Contribution to journalReview article

22 Citations (Scopus)
108 Downloads (Pure)

Abstract

The market for new psychoactive substances has increased markedly in recent years and there is now a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the total number of these compounds but their use and misuse has rapidly increased. Some of these benzodiazepines have only been patented, some of them have not been previously synthesised and the majority have never undergone clinical trials or tests. Despite their structural and chemical similarity, large differences exist between the benzodiazepines in their pharmacokinetic parameters and metabolic pathways and so they are not easily comparable. As benzodiazepines have been clinically used since the 1960s many analytical methods exist to quantify them in a variety of biological matrices and it is expected that these methods would also be suitable for the detection of benzodiazepines that are new psychoactive substances. Illicitly obtained benzodiazepines have been found to contain a wide range of compounds such as opiates which presents a problem since the use of them in conjunction with each other can lead to respiratory depression and death. The aim of this review is to collate the available information on these benzodiazepines and to provide a starting point for the further investigation of their pharmacokinetics which is clearly required.
Original languageEnglish
Pages (from-to)37-53
Number of pages17
JournalDrug Testing and Analysis
Volume10
Issue number1
Early online date4 May 2017
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Benzodiazepines
analytical method
Pharmacokinetics
matrix
market
Opiate Alkaloids
Metabolic Networks and Pathways
pharmacokinetics
Respiratory Insufficiency
Clinical Trials
detection
method
chemical
test
trial
parameter

Cite this

Manchester, Kieran R. ; Lomas, Emma C. ; Waters, Laura ; Dempsey, Fiona C. ; Maskell, Peter D. / The emergence of new psychoactive substance (NPS) benzodiazepines : a review. In: Drug Testing and Analysis. 2018 ; Vol. 10, No. 1. pp. 37-53.
@article{9a280549be8d4907b7d4532fbfd8547a,
title = "The emergence of new psychoactive substance (NPS) benzodiazepines: a review",
abstract = "The market for new psychoactive substances has increased markedly in recent years and there is now a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the total number of these compounds but their use and misuse has rapidly increased. Some of these benzodiazepines have only been patented, some of them have not been previously synthesised and the majority have never undergone clinical trials or tests. Despite their structural and chemical similarity, large differences exist between the benzodiazepines in their pharmacokinetic parameters and metabolic pathways and so they are not easily comparable. As benzodiazepines have been clinically used since the 1960s many analytical methods exist to quantify them in a variety of biological matrices and it is expected that these methods would also be suitable for the detection of benzodiazepines that are new psychoactive substances. Illicitly obtained benzodiazepines have been found to contain a wide range of compounds such as opiates which presents a problem since the use of them in conjunction with each other can lead to respiratory depression and death. The aim of this review is to collate the available information on these benzodiazepines and to provide a starting point for the further investigation of their pharmacokinetics which is clearly required.",
author = "Manchester, {Kieran R.} and Lomas, {Emma C.} and Laura Waters and Dempsey, {Fiona C.} and Maskell, {Peter D.}",
year = "2018",
month = "1",
doi = "10.1002/dta.2211",
language = "English",
volume = "10",
pages = "37--53",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

The emergence of new psychoactive substance (NPS) benzodiazepines : a review. / Manchester, Kieran R.; Lomas, Emma C.; Waters, Laura; Dempsey, Fiona C.; Maskell, Peter D.

In: Drug Testing and Analysis, Vol. 10, No. 1, 01.2018, p. 37-53.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The emergence of new psychoactive substance (NPS) benzodiazepines

T2 - a review

AU - Manchester, Kieran R.

AU - Lomas, Emma C.

AU - Waters, Laura

AU - Dempsey, Fiona C.

AU - Maskell, Peter D.

PY - 2018/1

Y1 - 2018/1

N2 - The market for new psychoactive substances has increased markedly in recent years and there is now a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the total number of these compounds but their use and misuse has rapidly increased. Some of these benzodiazepines have only been patented, some of them have not been previously synthesised and the majority have never undergone clinical trials or tests. Despite their structural and chemical similarity, large differences exist between the benzodiazepines in their pharmacokinetic parameters and metabolic pathways and so they are not easily comparable. As benzodiazepines have been clinically used since the 1960s many analytical methods exist to quantify them in a variety of biological matrices and it is expected that these methods would also be suitable for the detection of benzodiazepines that are new psychoactive substances. Illicitly obtained benzodiazepines have been found to contain a wide range of compounds such as opiates which presents a problem since the use of them in conjunction with each other can lead to respiratory depression and death. The aim of this review is to collate the available information on these benzodiazepines and to provide a starting point for the further investigation of their pharmacokinetics which is clearly required.

AB - The market for new psychoactive substances has increased markedly in recent years and there is now a steady stream of compounds appearing every year. Benzodiazepines consist of only a fraction of the total number of these compounds but their use and misuse has rapidly increased. Some of these benzodiazepines have only been patented, some of them have not been previously synthesised and the majority have never undergone clinical trials or tests. Despite their structural and chemical similarity, large differences exist between the benzodiazepines in their pharmacokinetic parameters and metabolic pathways and so they are not easily comparable. As benzodiazepines have been clinically used since the 1960s many analytical methods exist to quantify them in a variety of biological matrices and it is expected that these methods would also be suitable for the detection of benzodiazepines that are new psychoactive substances. Illicitly obtained benzodiazepines have been found to contain a wide range of compounds such as opiates which presents a problem since the use of them in conjunction with each other can lead to respiratory depression and death. The aim of this review is to collate the available information on these benzodiazepines and to provide a starting point for the further investigation of their pharmacokinetics which is clearly required.

U2 - 10.1002/dta.2211

DO - 10.1002/dta.2211

M3 - Review article

VL - 10

SP - 37

EP - 53

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

IS - 1

ER -